Paolo P. Ghia
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 331 publications
Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.
Journal: Lancet (London, England)
Published: May 06, 2026
EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation.
Journal: HemaSphere
Published: February 06, 2026
HS1 loss drives cytoskeletal dysregulation and reduces sensitivity to BTK inhibition in chronic lymphocytic leukemia.
Journal: Journal of leukocyte biology
Published: February 04, 2026
Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells.
Journal: Science translational medicine
Published: February 04, 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis.
Journal: Current medical research and opinion
Published: January 30, 2026
A Comprehensive Review of the Role of Zanubrutinib for Patients with Chronic Lymphocytic Leukemia.
Journal: Oncology and therapy
Published: January 28, 2026
Consensus-based ranking of determinants for frontline therapy selection in chronic lymphocytic leukemia: A conjoint analysis.
Journal: Critical reviews in oncology/hematology
Published: January 20, 2026
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.
Journal: The New England journal of medicine
Published: December 08, 2025
Fixed-duration ibrutinib-venetoclax for first-line treatment of patients with chronic lymphocytic leukemia: the REALITY-WW prospective real-world study cohort.
Journal: Future oncology (London, England)
Published: November 01, 2025
Last Updated: 09/26/2026